Pharmabiz
 

Gen-Probe gets US FDA nod for HIV diagnostic test

San DiegoMonday, October 9, 2006, 08:00 Hrs  [IST]

Gen-Probe announced that the US Food and Drug Administration (FDA) has granted marketing approval for the Aptima HIV-1 RNA qualitative assay. The assay may be used as an aid in the diagnosis of acute and primary HIV-1 infection, and to confirm HIV-1 infection in an individual whose specimen is repeatedly reactive (positive) for HIV-1 antibodies. The assay is the first FDA-approved qualitative nucleic acid test (NAT) for these intended uses. Gen-Probe expects to launch the assay in November in conjunction with the Aptima HCV (hepatitis C virus) RNA qualitative assay. Detection of HCV RNA is evidence of active HCV infection. The APTIMA HCV assay may be used to detect HCV RNA in individuals with antibody evidence of HCV infection and evidence of liver disease, individuals suspected to be actively infected with HCV with antibody evidence, and individuals at risk for HCV infection with antibodies to HCV. "We believe these two new qualitative viral products may fill a small yet important medical niche in the detection of two treatable but potentially life-threatening diseases, especially in light of new CDC guidelines that support increased testing for HIV, and new scientific publications regarding hepatitis C," said Steve Kondor, Gen-Probe's vice president of sales and marketing. Qualitative assays detect the presence of viral genetic material and give a "yes-no" answer as to whether the target virus is present. In contrast, quantitative assays are used to estimate the amount of genetic material present in a sample. Gen-Probe's new viral products are not approved for quantitative use. In September, the US Centers for Disease Control and Prevention (CDC) published new recommendations for health care providers that are designed to make voluntary HIV screening a routine part of medical care for all patients aged 13 to 64. The CDC estimated that more than 250,000 Americans are HIV-positive but unaware of their condition, and said that early diagnosis is critical in order for people with HIV to receive life-extending therapy. Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood.

 
[Close]